Skip to main content
. 2022 May 19;13:2799. doi: 10.1038/s41467-022-30387-4

Fig. 4. ASO treatment in a patient with C9ORF72-ALS decreases CSF DPR levels.

Fig. 4

a Poly(GR) levels in CSF were generally stable over time in two symptomatic and two asymptomatic patients with C9ORF72 mutations. b Longitudinal trend of poly(GR) levels in CSF from a larger cohort of patients with C9ORF72 mutations. c Longitudinal trend of poly(GA) levels in CSF from patients with C9ORF72 mutations. d After ASO treatment, CSF poly(GP), poly(GA), and poly(GR) levels in a patient with C9ORF72-ALS decreased over time. Note: colors in panels b, c do not indicate the same patients. The fifth time point value for symptomatic patient 2 in panel a and the last time point for poly(GR) value in panel b were above background but below the lower limit of detection and were not included. Source data are provided as a Source Data file.